Slimbiome study results

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease, diabetes and skincare, notes the latest results from the human studies carried out at Roehampton University, London on OptiBiotix’s SlimBiome®.

Study outcomes, awaiting publication, suggested SlimBiome® intake had a major impact on insulin response combined with significantly lower feelings of hunger, a lower desire to eat, and significantly higher levels of fullness within 15 minutes, for over two hours after consumption. This is one of four studies which have consistently shown SlimBiome® reduces hunger and food cravings leading to users both reducing the amount of food and changing the type of food they eat, to less calorie intense food leading to sustainable weight management. This suggests that SlimBiome® can be used as a natural alternative to the current anti-obesity drugs on the market.

These findings on the acute impact of one dose of SlimBiome® are consistent with those of a previous first study, also carried out by Professor Adele Costabile, published in the Journal of Functional Foods (November 2020) which showed that volunteers taking SlimBiome® for four weeks experienced a 21% reduction in cravings for sweet foods and a 30% reduction in cravings for savoury foods.

Stephen O’Hara, CEO of OptiBiotix Health plc commented: “We’re delighted to see these study results which continue to prove the efficacy of Slimbiome® to reduce hunger and food cravings which changes the amount and type of food people eat leading to sustainable weight management. The current anti-obesity drugs available on the market are not suitable for everyone, and Slimbiome® represents a natural alternative that can be widely used with no adverse side effects. Whilst using different mechanisms of action, SlimBiome^® and anti-obesity drugs work in a similar way by regulating insulin response and promoting the feelings of fullness by slowing down stomach emptying.”

SlimBiome® is available here in sachets as SlimBiome Medical®/SlimBiome X3 or in meal replacements, bars, gummies, and soups/porridges and is increasingly being used by major sports nutrition brands to support lean body development.

For the full press release issued by the University of Roehampton, see below.

The Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

OptiBiotix Health plc   Neil Davidson, Chairman Stephen O’Hara, Chief Executive	www.optibiotix.com Contact via Walbrook below
Peterhouse Capital Limited (Broker) Duncan Vasey / Lucy Williams	Tel: 020 7220 9797
Walbrook PR Ltd Anna Dunphy	Mob: 07876 741 001

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome – the collective genome of the microbes in the body – in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company’s current areas of focus include obesity, cardiovascular health, and diabetes. 

This communication is a “Reach” announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.